Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGFR | P43088 | 16/20 | 1.00 |
| ▸ | PTGER3 | P43115 | 5/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.81 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.81 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.78 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.78 |
| ▸ | THRB | P10828 | 1/20 | 0.78 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluprostenol SCHEMBL16414497 | 1.00 | PTGFR (1.00) | PTGFRPTGER3ABCC4ABCB11TBXA2R | |
| Fluprostenol SCHEMBL2744986 | 1.00 | PTGFR (1.00) | PTGFRPTGER3ABCC4ABCB11TBXA2R | |
| Fluprostenol SCHEMBL10015915 | 1.00 | PTGFR (1.00) | PTGFRPTGER3ABCC4ABCB11TBXA2R | |
| Fluprostenol SCHEMBL24342036 | 1.00 | PTGFR (1.00) | PTGFRPTGER3ABCC4ABCB11TBXA2R | |
| Fluprostenol SCHEMBL13260302 | 1.00 | PTGFR (1.00) | PTGFRPTGER3ABCC4ABCB11TBXA2R | |
| Fluprostenol SCHEMBL24342073 | 1.00 | PTGFR (1.00) | PTGFRPTGER3ABCC4ABCB11TBXA2R | |
| Fluprostenol SCHEMBL6750653 | 1.00 | PTGFR (1.00) | PTGFRPTGER3ABCC4ABCB11TBXA2R | |
| Fluprostenol SCHEMBL230607 | 1.00 | PTGFR (1.00) | PTGFRPTGER3ABCC4ABCB11TBXA2R | |
| Fluprostenol SCHEMBL20860290 | 1.00 | PTGFR (1.00) | PTGFRPTGER3ABCC4ABCB11TBXA2R | |
| Fluprostenol SCHEMBL3364535 | 1.00 | PTGFR (1.00) | PTGFRPTGER3ABCC4ABCB11TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150031898-A1 | PROCESS FOR PREPARATION OF PROSTAGLANDIN F2 ALPHA ANALOGUES | INSTYTUT FARMACEUTYCZNY (PL) | 2015-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031898-A1 | PROCESS FOR PREPARATION OF PROSTAGLANDIN F2 ALPHA ANALOGUES | PTGES, PTGIS, PTGES2 | PTGFR 10/4885PTGER3 23/4885ABCC4 3772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.